Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.
J Comp Eff Res
; 7(8): 785-795, 2018 08.
Article
en En
| MEDLINE
| ID: mdl-29860879
ABSTRACT
Aim:
To evaluate the cost-effectiveness of the novel all-oral direct-acting antiviral regimen daclatasvir + asunaprevir (DUAL), versus interferon-based regimens for the treatment of chronic hepatitis C virus genotype 1b infection.Methods:
Inputs for a lifetime Markov model were sourced from clinical trials and published literature. Outputs include disease management costs, life expectancy, quality-adjusted life-years and cost-effectiveness. Sensitivity analyses assessed the drivers of cost-effectiveness and sustained virologic response thresholds at which DUAL is cost-saving.Results:
DUAL was associated with discounted incremental quality-adjusted life-years of 1.29-3.85 and incremental life-years of 0.85-2.59 per patient, with discounted lifetime cost savings of USD$1415-8525. Associated sustained virologic response rates could fall to 45.1-84.8%, while remaining dominant.Conclusion:
Treatment with DUAL provides significant clinical benefit, while accruing lower lifetime costs.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Antivirales
/
Sulfonamidas
/
Hepatitis C Crónica
/
Imidazoles
/
Isoquinolinas
Tipo de estudio:
Health_economic_evaluation
Aspecto:
Patient_preference
Límite:
Humans
/
Male
País/Región como asunto:
Asia
Idioma:
En
Revista:
J Comp Eff Res
Año:
2018
Tipo del documento:
Article
País de afiliación:
China